Factory 99% Dolutegravir Powder CAS 1051375-16-6 Chemical Intermediate Anti-Virul Dolutegravir

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A632
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Dolutegravir
• CAS: 1051375-16-6
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Anti-Virul
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Dolutegravir
Appearance	White Powder
CAS NO.	1051375-16-6
MF	C20H15N5O7
Storage	Keep in a cool, dry, dark location

 

Dolutegravir is an antiretroviral medication that belongs to the class of integrase inhibitors. It works by preventing the HIV virus from integrating its genetic material into the host cell's DNA, thereby blocking the virus's replication cycle.

 

1. HIV Treatment: Dolutegravir is a key component in combination antiretroviral therapy (cART) for the treatment of HIV-1 infection. It is often prescribed in combination with other antiretroviral agents to achieve viral suppression.
2. First-line Therapy: Due to its high efficacy and low toxicity, Dolutegravir is recommended as a first-line treatment option for HIV-1 infection by many international guidelines.
3. Treatment-experienced Patients: It is also effective in patients who have previously failed other antiretroviral therapies, providing an alternative option for those with resistant virus strains.

1. Integrase Inhibition: By inhibiting the HIV integrase enzyme, Dolutegravir prevents the virus from inserting its genetic material into the host cell's DNA, thus stopping the production of new virus particles.
2. Viral Suppression: When used in combination with other antiretroviral drugs, Dolutegravir can effectively suppress HIV viral load to undetectable levels, reducing the risk of disease progression and transmission.
3. Improved Outcomes: By achieving and maintaining viral suppression, Dolutegravir contributes to improved clinical outcomes, including reduced mortality and morbidity associated with HIV/AIDS.